Piper Sandler Maintains Overweight on Solid Biosciences, Raises Price Target to $18
Solid Biosciences Inc.
Solid Biosciences Inc. SLDB | 0.00 |
Piper Sandler analyst Biren Amin maintains Solid Biosciences (NASDAQ:
SLDB) with a Overweight and raises the price target from $17 to $18.
